Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Company Announcement
Covered in this story
Call it yourself
No calls on $PL=F yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Platinum →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.